Archford Capital Strategies’s Myriad Genetics MYGN Stock Holding History

Archford Capital Strategies’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-15	Closed	-$1K	–	626
2018 Q2	$1K	Hold	15	–	–	﹤0.01%	637
2018 Q1	$1K	Buy	+15	New	+$508	﹤0.01%	587
2017 Q2	–	Sell	-15	Closed	–	–	467
2017 Q1	$0	Hold	15	–	–	﹤0.01%	747
2016 Q4	$0	Hold	15	–	–	﹤0.01%	711
2016 Q3	$0	Hold	15	–	–	﹤0.01%	689
2016 Q2	$0	Buy	+15	New	+$521	﹤0.01%	756
2016 Q1	–	Sell	-15	Closed	-$1K	–	441
2015 Q4	$1K	Hold	15	–	–	﹤0.01%	772
2015 Q3	$1K	Hold	15	–	–	﹤0.01%	636
2015 Q2	$1K	Hold	15	–	–	﹤0.01%	605
2015 Q1	$531	Hold	15	–	–	﹤0.01%	692
2014 Q4	$1K	Hold	15	–	–	﹤0.01%	630
2014 Q3	$1K	Hold	15	–	–	﹤0.01%	628
2014 Q2	$583	Hold	15	–	–	﹤0.01%	840
2014 Q1	$513	Buy	+15	New	+$465	﹤0.01%	804

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Archford Capital Strategies's MYGN Position: Q3 2018 in Review

Archford Capital Strategies sold out of Myriad Genetics (MYGN) in Q3 2018, closing a stake of 15 shares — an estimated $1K sold.

Archford Capital Strategies first reported a position in MYGN in Q1 2014 and held it in 14 quarters. The position peaked at $1K in Q2 2018. 284 funds tracked by Wall St. Rank hold MYGN as of Q3 2018.

Archford Capital Strategies reported no remaining Myriad Genetics position as of Q3 2018 after selling out during the quarter.
Archford Capital Strategies sold 15 Myriad Genetics shares in Q3 2018, an estimated $1K.
Archford Capital Strategies first reported a position in Myriad Genetics in Q1 2014 and held it in 14 quarters.
Archford Capital Strategies's Myriad Genetics position peaked at $1K in Q2 2018.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2018.

Based on Archford Capital Strategies's 13F filing for Q3 2018, filed 14 Nov 2018.